Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral doxycycline with bevacizumab in diabetic patients with clinically significant macular edema
IRCT20200720048150N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Nov 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of doxycycline and bevacizumab in type 2 diabetes mellitus (T2DM) and diabetic macular edema (DME), sponsored by Ahvaz Jundishapur University of Medical Sciences. Started Nov 2018; status: completed.
02
Drugs
doxycyclinebevacizumab
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic macular edema (DME)
Beyond the preview
Go deeper on IRCT20200720048150N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200720048150N1.